Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.

E. Richelson

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

In the past decade, 8 new antidepressants were approved for use in the United States by the US Food and Drug Administration. Six of these have been marketed in the United States since 1992. Two additional drugs marketed outside the United States as antidepressants have been approved in this country for obsessive-compulsive disorder. Together with the conventional antidepressants, the new ones, and the 2 drugs available off-label, the physician can choose from a list of 22 compounds to treat the depressed patient. This article reviews theories about the mechanisms of action of antidepressants and the basic pharmacology of the newer-generation drugs in relation to the older compounds. We hope this information is of use to the clinician in treating acute depression with pharmacologic agents.

Original languageEnglish (US)
Pages (from-to)17-30
Number of pages14
JournalClinical cornerstone
Volume1
Issue number4
DOIs
StatePublished - 1999

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.'. Together they form a unique fingerprint.

Cite this